Copaxone Growth Helps Teva Offset Declining Generics Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Strong sales for the multiple sclerosis therapy eased the impact of $100 mil. decline in U.S. generics revenue.
You may also be interested in...
Teva’s Copaxone Shows Continued Efficacy In Long-Term Trial; Study Extended To 15 Years
Teva reported no cases of immune-mediated adverse events in a 10-year study of its multiple sclerosis therapy glatiramer.
Teva’s Copaxone Shows Continued Efficacy In Long-Term Trial; Study Extended To 15 Years
Teva reported no cases of immune-mediated adverse events in a 10-year study of its multiple sclerosis therapy glatiramer.
Teva Ceases Oral Copaxone Development
The company said it is still considering development of “various non-parenteral formulations” for the MS therapy.